DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 129 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is 2.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,771,248 | +31.1% | 551,854 | +27.6% | 0.00% | 0.0% |
| Q2 2023 | $5,165,148 | +76.0% | 432,592 | +97.1% | 0.00% | 0.0% |
| Q1 2023 | $2,934,996 | -39.5% | 219,521 | -2.6% | 0.00% | 0.0% |
| Q4 2022 | $4,847,790 | +7.6% | 225,269 | +0.1% | 0.00% | 0.0% |
| Q3 2022 | $4,507,000 | +32.2% | 225,050 | +18.1% | 0.00% | 0.0% |
| Q2 2022 | $3,410,000 | +101.9% | 190,510 | +11.9% | 0.00% | – |
| Q1 2022 | $1,689,000 | -3.3% | 170,299 | +64.3% | 0.00% | – |
| Q4 2021 | $1,747,000 | -25.0% | 103,677 | +5.7% | 0.00% | – |
| Q3 2021 | $2,328,000 | +702.8% | 98,099 | +671.3% | 0.00% | – |
| Q2 2021 | $290,000 | – | 12,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 6,964,301 | $139,495,000 | 56.26% |
| PATHWAY CAPITAL MANAGEMENT, LP | 403,127 | $8,075,000 | 25.88% |
| Atlas Venture Life Science Advisors, LLC | 8,169,171 | $163,628,000 | 18.06% |
| RA Capital Management | 7,040,622 | $141,024,000 | 3.01% |
| COMMODORE CAPITAL LP | 739,661 | $14,815,000 | 2.38% |
| Nicholas Investment Partners, LP | 757,407 | $15,171,000 | 1.41% |
| Boxer Capital, LLC | 1,189,943 | $23,835,000 | 1.34% |
| Parkman Healthcare Partners LLC | 212,191 | $4,250,000 | 1.21% |
| TANG CAPITAL MANAGEMENT LLC | 400,000 | $8,012,000 | 0.98% |
| Samsara BioCapital, LLC | 196,425 | $3,934,000 | 0.92% |